Генетические варианты rs1049255 CYBA и rs2333227 MPO ассоциированы с предрасположенностью к ишемической болезни сердца у русских жителей Центральной России

Цель    Изучение ассоциации однонуклеотидных полиморфизмов rs1049255 CYBA и rs2333227 MPO с развитием ишемической болезни сердца (ИБС) у русских жителей Центральной России.

Материал и методы  Материалом для исследования послужили образцы ДНК 436 пациентов с ИБС (265 мужчин, 171 женщина; средний возраст 61 год) и 370 относительно здоровых добровольцев, сопоставимых по полу и возрасту (209 мужчин, 161 женщина; средний возраст 60 лет). Генотипирование проводили путем дискриминации аллелей с помощью TaqMan-зондов.

Результаты   Сравнительный анализ частот генотипов (лог-аддитивная регрессионная модель) показал, что SNP rs1049255 CYBA (отношение шансов – ОШ 0,79 при 95 % доверительном интервале – ДИ от 0,65 до 0,96; p=0,02) и rs2333227 MPO (ОШ 0,72 при 95 % ДИ от 0,55 до 0,95; p=0,02) ассоциировались с пониженным риском развития ИБС, с учетом поправки на пол, возраст. Анализ эффектов, специфических для пола, выявил, что протективный эффект rs1049255 CYBA проявляется только у мужчин (OШ 0,72 при 95 % ДИ от 0,55 до 0,94; p=0,16).

Заключение     Установлен протективный эффект rs1049255 CYBA и rs2333227 MPO относительно развития ИБС у русских. Протективный эффект rs1049255 CYBA наблюдается только у мужчин.

1. Laslett LJ, Alagona P, Clark BA, Drozda JP, Saldivar F, Wilson SR et al. The Worldwide Environment of Cardiovascular Disease: Prevalence, Diagnosis, Therapy, and Policy Issues. Journal of the American College of Cardiology. 2012;60(25):S1–49. DOI: 10.1016/j.jacc.2012.11.002

2. Lubrano V, Pingitore A, Traghella I, Storti S, Parri S, Berti S et al. Emerging Biomarkers of Oxidative Stress in Acute and Stable Coronary Artery Disease: Levels and Determinants. Antioxidants. 2019;8(5):115. DOI: 10.3390/antiox8050115

3. Голубенко М.В., Бабушкина Н.П., Зарубин А.А., Салахов Р.Р., Макеева О.А., Маркова В.В. и др. Ассоциация вариантов гаплогруппы Н1 митохондриальной ДНК с риском сердечно-сосудистых катастроф. Научные результаты биомедицинских исследований. 2019;5(4):19-31. DOI: 10.18413/2658-6533-2019-5-4-0-2

4. Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal. 2020;41(24):2313–30. DOI: 10.1093/eurheartj/ehz962

5. Sorescu D, Weiss D, Lassègue B, Clempus RE, Szöcs K, Sorescu GP et al. Superoxide Production and Expression of Nox Family Proteins in Human Atherosclerosis. Circulation. 2002;105(12):1429–35. DOI: 10.1161/01.CIR.0000012917.74432.66

6. Prieto-Bermejo Rodrigo, Hernández-Hernández Angel. The Importance of NADPH Oxidases and Redox Signaling in Angiogenesis. Antioxidants. 2017;6(2):32. DOI: 10.3390/antiox6020032

7. Liu C, Rennie WA, Carmack CS, Kanoria S, Cheng J, Lu J et al. Effects of genetic variations on microRNA: target interactions. Nucleic Acids Research. 2014;42(15):9543–52. DOI: 10.1093/nar/gku675

8. Macías-Reyes A, Rodríguez-Esparragón F, Caballero-Hidalgo A, Hernández-Trujillo Y, Medina A, Rodríguez-Pérez JC. Insight into the role of CYBA A640G and C242T gene variants and coronary heart disease risk. A case-control study. Free Radical Research. 2008;42(1):82–92. DOI: 10.1080/10715760701796918

9. Liu S, Li X, Wang J, Ji J, Liu J, Lin Y et al. The rs9932581 and rs1049255 Polymorphisms in CYBA is not Associated with Preeclampsia in Chinese Han Women. Cellular Physiology and Biochemistry. 2016;39(4):1471–8. DOI: 10.1159/000447850

10. Winterbourn CC, Vissers MC, Kettle AJ. Myeloperoxidase: Current Opinion in Hematology. 2000;7(1):53–8. DOI: 10.1097/00062752-200001000-00010

11. Zelzer S, Enko D, Pilz S, Tomaschitz A, März W, Meinitzer A. Myeloperoxidase, asymmetric dimethyl-arginine and the renin-angiotensinaldosterone-system in cardiovascular risk patients: Cross-sectional findings from the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clinical Biochemistry. 2017;50(13–14):739–45. DOI: 10.1016/j.clinbiochem.2017.03.013

12. Desikan R, Narasimhulu CA, Khan B, Rajagopalan S, Parthasarathy S. Myeloperoxidase (MPO): Do We Need Inhibitors? In: Mechanisms of Vascular Defects in Diabetes Mellitus [ISBN: 978-3-319-60323-0]. Kartha CC, Ramachandran S, Pillai RM, editors -Cham: Springer International Publishing; 2017. - P. 535-571. [DOI: 10.1007/978-3-319-60324-7_24].

13. Afshinnia F, Zeng L, Byun J, Gadegbeku CA, Magnone MC, Whatling C et al. Myeloperoxidase Levels and Its Product 3-Chlorotyrosine Predict Chronic Kidney Disease Severity and Associated Coronary Artery Disease. American Journal of Nephrology. 2017;46(1):73–81. DOI: 10.1159/000477766

14. Nikpoor B, Turecki G, Fournier C, Théroux P, Rouleau GA. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. American Heart Journal. 2001;142(2):336–9. DOI: 10.1067/mhj.2001.116769

15. Tang N, Wang Y, Mei Q. Myeloperoxidase G-463A polymorphism and susceptibility to coronary artery disease: A meta-analysis. Gene. 2013;523(2):152–7. DOI: 10.1016/j.gene.2013.03.131

16. Chang C, Gao B, Liu Z, Mao J, Jiang G. The myeloperoxidase -463G/A polymorphism and coronary artery disease risk: A meta-analysis of 1938 cases and 1990 controls. Clinical Biochemistry. 2013;46(16–17):1644–8. DOI: 10.1016/j.clinbiochem.2013.09.002

17. Mandsorwale D, Nagtilak S, Lalchandani A, Srivastava AK. Role of-463 G/A genetic polymorphism & myeloperoxidase activity in prediction of cardiovascular disease. Scholars Journal of Applied Medical Sciences. 2014;2(4D):1402–7. [Av. at: http://saspublisher.com/wp-content/uploads/2014/07/SJAMS24D1402-1407.pdf]

18. Polonikov A, Kharchenko A, Bykanova M, Sirotina S, Ponomarenko I, Bocharova A et al. Polymorphisms of CYP2C8 , CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population. Gene. 2017;627:451–9. DOI: 10.1016/j.gene.2017.07.004

19. Bushueva O, Solodilova M, Ivanov V, Polonikov A. Gender-specific protective effect of the -463G>A polymorphism of myeloperoxidase gene against the risk of essential hypertension in Russians. Journal of the American Society of Hypertension. 2015;9(11):902–6. DOI: 10.1016/j.jash.2015.08.006

20. Packer BR, Yeager M, Burdett L, Welch R, Beerman M, Qi L et al. SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Research. 2006;34(90001):D617–21. DOI: 10.1093/ nar/gkj151

21. Katsuyama M. NOX/NADPH Oxidase, the Superoxide-Generating Enzyme: Its Transcriptional Regulation and Physiological Roles. Journal of Pharmacological Sciences. 2010;114(2):134–46. DOI: 10.1254/jphs.10R01CR

22. Schirmer M, Hoffmann M, Kaya E, Tzvetkov M, Brockmöller J. Genetic polymorphisms of NAD(P)H oxidase: variation in subunit expression and enzyme activity. The Pharmacogenomics Journal. 2008;8(4):297–304. DOI: 10.1038/sj.tpj.6500467

23. Dantas A, Franco M, Silva-Antonialli MM, Tostes RC, Fortes ZB, Nigro D et al. Gender differences in superoxide generation in microvessels of hypertensive rats: role of NAD(P)H-oxidase. Cardiovascular Research. 2004;61(1):22–9. DOI: 10.1016/j.cardiores.2003.10.010

24. Dikalov S, Itani H, Richmond B, Arslanbaeva L, Vergeade A, Rahman SMJ et al. Tobacco smoking induces cardiovascular mitochondrial oxidative stress, promotes endothelial dysfunction, and enhances hypertension. American Journal of Physiology-Heart and Circulatory Physiology. 2019;316(3):H639–46. DOI: 10.1152/ajpheart.00595.2018

25. Baldus S, Rudolph V, Roiss M, Ito WD, Rudolph TK, Eiserich JP et al. Heparins Increase Endothelial Nitric Oxide Bioavailability by Liberating Vessel-Immobilized Myeloperoxidase. Circulation. 2006;113(15):1871–8. DOI: 10.1161/CIRCULATIONAHA.105.590083

26. Yang J, Cheng Y, Ji R, Zhang C. Novel model of inflammatory neointima formation reveals a potential role of myeloperoxidase in neointimal hyperplasia. American Journal of Physiology-Heart and Circulatory Physiology. 2006;291(6):H3087–93. DOI: 10.1152/ajpheart.00412.2006

27. Rodríguez-Pla A, Bosch-Gil JA, Rosselló-Urgell J, Huguet-Redecilla P, Stone JH, Vilardell-Tarres M. Metalloproteinase-2 and -9 in Giant Cell Arteritis: Involvement in Vascular Remodeling. Circulation. 2005;112(2):264–9. DOI: 10.1161/CIRCULATIONAHA.104.520114

28. Yao C, Chen G, Song C, Keefe J, Mendelson M, Huan T et al. Genome‐ wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease. Nature Communications. 2018;9(1):3268. DOI: 10.1038/s41467-018-05512-x